Plain-English translation of NCT02863692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term tracking study for people diagnosed with chronic lymphocytic leukemia (CLL) or related blood cancers. Rather than testing a new drug, this registry collects health information from thousands of patients over many years to understand how current treatments — like rituximab combined with chemotherapy — affect survival, quality of life, and late-appearing side effects.
Most clinical trials follow patients for only 1–2 years, but serious side effects like secondary cancers or infections can appear much later. This registry exists to answer important questions about whether current treatments truly improve long-term survival and what long-term risks patients should be aware of.
You likely qualify if…
You likely don't qualify if…
As a participant, you would share your medical history and allow researchers to follow your health over time through medical records and periodic check-ins. There are no study drugs or new treatments to take — instead, you continue your regular cancer care while researchers track how you're doing and what happens as years pass. The study aims to enroll 8,000 patients and follow them for many years to build a complete picture of long-term outcomes.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Germany
Sponsor
German CLL Study Group
Enrollment target
~8,000 participants
Started
August 2013
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anna-Maria Fink, MD
German CLL Study Group, Department I of Internal Medicine University Hospital Cologne
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.